Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Alfa Cytology offers comprehensive solutions for the development of DNA vaccines, aiding in meeting various vaccine requirements and accelerating the progression of your leukemia DNA vaccine development project towards clinical trials. This approach, utilizing DNA vaccines derived from leukemia-specific or leukemia-associated antigens, presents an appealing method for immunotherapy to enhance overall survival rates.
DNA vaccines are plasmids designed to deliver genes encoding tumor antigens, triggering or enhancing adaptive immune responses against tumor cells carrying tumor antigens. Most leukemia DNA vaccines are still in development, with only clinical trial stages reached. Researchers are investigating vaccines that could prevent cancer recurrence. Currently, no approved vaccines for blood cancer are available.
Fig. 1. Immune activation induced by DNA vaccines. (Lopes, A. et al., 2019)
Our services assist you in exploring and thoroughly investigating various aspects of DNA-based vaccine administration, paving the way for advancements in leukemia treatment. We offer development services for the following types of DNA vaccines to cater to your specific needs.
Chimeric DNA Vaccines
Our services facilitate the development of Chimeric DNA vaccines. These vaccines incorporate foreign elements such as proteins or peptides extracted from another species, which exhibit significant homology with their endogenous counterparts.
MUC1-based DNA Vaccines
We specialize in the design of a chimeric MUC-1 DNA vaccine for our clients, which incorporates the mucin gene encoding MUC-1. Recombinant eukaryotic vectors expressing MUC-1 are introduced into animal models via intramuscular administration, thereby stimulating T cells and B cells.
Neoantigen DNA Vaccines
In light of these newly identified epitopes in leukemia, we offer development services for DNA vaccines. Our aim is to assist our clients in successfully developing personalized and customized therapies.
Polyepitope DNA Vaccines
The incorporation of diverse target epitopes into polyepitope DNA vaccines, using a minigene construct, enables the induction of cytotoxic T lymphocyte (CTL) responses against a wide repertoire of targets.
DNA vaccines can be administered through various routes to facilitate the entry of gene sequences into the cell nucleus. Several delivery methods have been investigated to enhance the efficacy of non-viral gene therapies, with electroporation proving to be a favorable approach. Considering the complexity and diverse requirements of delivery methods, we offer tailored services for the development of optimal DNA vaccine delivery approaches based on your specific needs, including but not limited to the following.
LAA Selection
Identify specific LAA that are expressed by leukemia cells and have the potential to elicit an immune response. Design the DNA sequence encoding the selected antigens.
Construction of Expression Vectors
Generate the target gene sequence from DNA and amplify the target gene sequence. Clone the amplified target gene fragment into an expression vector.
Enhancement of Immune Response
Select appropriate adjuvants and injection methods to enhance the induced immune response.
In Vivo Testing
Administer the vaccine into an animal model and evaluate the expression of the antigen as well as the induced immune response.
If you are seeking a collaborative partner for the development of DNA vaccines for leukemia, please contact our team. Alfa Cytology are committed to providing professional advice, high-quality services, and comprehensive support to help you make breakthroughs in leukemia treatment.
Reference